Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
781-800 of 2,120 trials

Inflammatory Bowel Disease: Adalimumab-680LT Study

We are investigating the safety and imaging of a new version of adalimumab for people with inflammatory bowel diseases. This study aims to see how well the drug targets inflammation and its potential effects on health.

Inflammatory Bowel Disease (IBD)6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInfectious Diseases

Meningioma Treatment: Everolimus and 177Lu-DOTATATE

We are studying a new combination treatment for patients with grades 2 and 3 refractory meningioma. The goal is to see if this approach can help improve survival and manage tumor growth.

Malignant Meningiomas1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology

Whooping Cough Vaccine: Tdap-IPV Study

We are studying whether a booster shot of the Tdap-IPV vaccine helps prevent colonization by whooping cough bacteria in healthy adults after exposure. This research aims to improve vaccination strategies against whooping cough.

Whooping Cough≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Chronic Pelvic Pain: Esketamine Infusion Study

We are investigating whether an 8-hour infusion of esketamine can help reduce chronic pelvic pain in individuals with endometriosis. The study also examines treatment experiences and overall quality of life.

EndometriosisMonitoring phase (IV)Standard MedicinesGynecology and ObstetricsPsychiatry

Head and Neck Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab in patients with recurrent or metastatic head and neck squamous cell carcinoma. This trial looks at its use alone and with other standard treatments to see how well it works.

Recurrent Head and Neck CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

B-cell Acute Lymphoblastic Leukemia: CD19-CAR T Cell Therapy

We are testing a new type of CAR T cell therapy for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. The study aims to evaluate the safety and appropriate dosage of this treatment.

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Chronic Lymphocytic Leukemia: Acalabrutinib vs. Venetoclax

We are comparing two treatment combinations for newly diagnosed chronic lymphocytic leukemia patients to see which is more effective and safer. We will also look at how these treatments affect patients' quality of life.

Chronic Lymphocytic Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Nipocalimab for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

We are studying whether nipocalimab can help adults with CIDP delay relapse and improve their symptoms compared to a placebo. This trial will also assess the safety of the treatment.

Chronic Inflammatory Demyelinating PolyneuropathyEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Scleroderma: Stem Cell Injections for Digital Ulcers

We are studying if injections of cultured fat cells can help heal stubborn digital ulcers in patients with scleroderma. This trial compares the treatment to a placebo to evaluate its effectiveness and safety.

Systemic Sclerosis>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Stroke Treatment Study: Tirofiban vs. Aspirin

We are comparing the effectiveness and safety of tirofiban and aspirin for patients with acute ischemic stroke caused by tandem lesions. This study aims to find out which treatment better prevents complications and improves recovery.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyNeurology

Advanced Epithelial Ovarian Cancer: Radspherin® Treatment

We are studying whether Radspherin® can improve survival and quality of life for patients with advanced ovarian cancer and peritoneal metastasis. This trial focuses on those scheduled for chemotherapy and surgery.

Peritoneal Carcinomatosis>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Systemic Lupus Erythematosus: Ianalumab Study

We are evaluating a new medication, ianalumab, for patients with systemic lupus erythematosus to see if it helps improve symptoms and reduce flare-ups compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementRheumatology

Advanced Solid Tumors: D3S-001 Treatment Study

We are testing the safety and tolerability of D3S-001, alone or with other cancer medicines, for adults with advanced solid tumors that have a KRAS p.G12C mutation. This study aims to understand how the treatment works and its effects on tumors.

Advanced Solid Tumors with a KRAS p.G12C MutationSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Seasonal Allergic Rhinitis: PQ Grass Treatment for Kids

We are studying a new treatment for children and teens with seasonal allergic rhinitis caused by grass pollen. The goal is to see if it helps reduce symptoms and is safe for long-term use.

Allergic Rhinitis and Conjunctivitis>2 yearsConfirmation phase (III)>20 visitsStandard MedicinesCost ReimbursementPartially RemoteAllergologyPediatrics

Ravulizumab for Children with NMOSD

We are studying the safety and effectiveness of Ravulizumab in children and adolescents with NMOSD. This trial aims to see how it affects their neurological function and overall quality of life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Allergic Rhinitis: New Immunotherapy for Dust Mite Allergy

We are studying a new treatment for people aged 12 to 65 with allergic rhinitis caused by house dust mites. The trial will evaluate its effectiveness and safety compared to a placebo.

Allergic Rhinitis and Asthma1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesAllergologyInternal Medicine

Allergic Rhinitis: New Immunotherapy for House Dust Mite Allergy

We are studying a new treatment for people aged 12 to 65 with allergic rhinitis caused by house dust mites. The trial will evaluate its effectiveness and safety compared to a placebo.

Allergic Rhinitis and Asthma6-12 monthsConfirmation phase (III)Investigational MedicinesAllergologyPulmonology

Lupus Nephritis: Ianalumab Study

We are studying whether ianalumab can improve kidney function in people with active lupus nephritis compared to a placebo. This trial also looks at the safety and tolerability of the treatment.

Lupus Nephritis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNephrologyRheumatology

Neuroendocrine Tumors: Personalized vs. Standard RadioTherapy

We are comparing personalized radionuclide therapy with standard treatment for patients with neuroendocrine tumors. The goal is to see which approach is safer and more effective in shrinking tumors and improving quality of life.

Neuroendocrine Tumors6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Multiple Myeloma: Treatment-Free Interval Study

We are exploring whether a treatment-free interval is safe and effective for newly diagnosed multiple myeloma patients receiving a combination of Daratumumab, Lenalidomide, and Dexamethasone. The study aims to compare the effects of continuous treatment versus a break in therapy.

Multiple Myeloma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology